CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.66 USD | -0.38% |
|
-3.15% | +22.82% |
| May. 07 | Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Presentation Operator MessageOperator (Operator)Welcome to the Curis Virtual Annual Meeting of...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
04:30pm
- Business Update Call
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.66
USD
Average target price
79.8
USD
Spread / Average Target
+409.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.82% | 92.66M | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- CRIS Stock
- News Curis, Inc.
- Transcript : Curis, Inc. - Shareholder/Analyst Call